Product Pipeline | Regen BioPharma, Inc.

Small Molecules Targeting Cancer and Autoimmunity

Regen has identified and filed patents on small molecules that activate and inhibit a novel gene (NR2F6) which controls how the immune system reacts to cancer cells and to inflammatory responses.
  • Objective is to identify small molecules that can activate and inhibit NR2F6
  • ​Currently in pre-clinical development 
  • Initial indications (inhibitor): bladder cancer, myelodysplastic syndrome, lung cancer
  • Initial indications (activator): rheumatoid arthritis, inflammatory bowel disease, psoriasis
  • Additional indications include solid tumors, acute leukemia and GVHD

HemaXellerate

Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.
  • Fat stem cell based product to treat bone marrow that has been damaged
  • Bone marrow damage occurs from radiation, chemo, or chronic conditions
  • HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow 
  • ​United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)

dCellVax 

Breast Cancer – dCellVax - IND #16200
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
  • 10 advanced breast cancer patients
  • Efficacy endpoints at 6 and 12 months
  • Establishment of safety will allow for rapid expansion of patient numbers 
  • Currently addressing FDA questions with Dr. Santosh Kesari, head of UCSD Neuro-Oncology program 

DiffronC

Myelodysplastic Syndrome Gene Silencing – DiffronC
DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells.
  • siRNA silencing of our newly discovered cancer stem cell target gene
  • Silencing using DiffronC induces differentiation of cancer cells 
  • Initial indication is treatment of myelodysplastic syndrome 
  • Other indications include solid tumors and acute leukemia

Telomeres & Genomic Integrity

Stem cells and cancer cells have found ways of maintaining their telomeres in a state that prevents senescence. Our research in to the cancer stem cell has given us a molecular pathway that can be manipulated to expand stem cells and maintain telomeres.
  • Telomeres are protective structures at the ends of chromosomes that enable cell divisions
  • Telomere attrition is involved in aging, cancer and genetic mutations 
  • We are developing drugs that modulate telomere maintenance 
  • In pre-clinical development for indications of solid cancers and acute leukemia